In a welcome move, GSK ADR saw its Relative Strength Rating improve from 69 to 78 on Wednesday.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matched up against all other stocks.
History reveals that the best-performing stocks tend to have an RS Rating north of 80 as they launch their largest climbs. See if GSK ADR can continue to show renewed price strength and clear that threshold.
GSK ADR is working on a consolidation with a 45.92 entry. See if it can clear the breakout price in volume at least 40% above average.
While EPS growth decreased in the company's most recent quarterly report from 8% to -22%, the top line grew 4%, up from -1% in the prior report.
The company earns the No. 4 rank among its peers in the Medical-Diversified industry group. Eli Lilly is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
